## Mycophenolate Mofetil (MMF): Mechanism of Toxicity ### Understanding MMF's Selective Immunosuppression and Its Limits **Key Point:** MMF is a prodrug of mycophenolic acid (MPA) that selectively inhibits inosine monophosphate dehydrogenase (IMPDH). While T and B lymphocytes rely predominantly on the Type II IMPDH isoform, other rapidly dividing cells (intestinal epithelium, bone marrow) also express IMPDH and are vulnerable to toxicity. ### Mechanism of Action and Selectivity MMF undergoes rapid hydrolysis to mycophenolic acid (MPA), which is the active metabolite. MPA inhibits IMPDH, a key enzyme in the de novo pathway of guanosine nucleotide synthesis: $$\text{Inosine monophosphate (IMP)} \xrightarrow{\text{IMPDH}} \text{Xanthosine monophosphate (XMP)} \rightarrow \text{GTP}$$ **High-Yield:** Lymphocytes (T and B cells) depend almost exclusively on the de novo pathway for guanosine synthesis and lack the salvage pathway enzyme hypoxanthine-guanine phosphoribosyltransferase (HGPRT) in sufficient quantity. This creates relative selectivity for immune suppression. However, **other rapidly dividing cells also express IMPDH** and are therefore susceptible to MMF toxicity: - Intestinal epithelial cells (causing diarrhea, abdominal pain) - Bone marrow progenitors (causing leukopenia, anemia, thrombocytopenia) ### Why Option 2 Is Incorrect (Common Misconception) **Warning:** Option 2 suggests "direct mucosal injury from MPA metabolite accumulation." While GI toxicity is real, it is NOT due to direct chemical injury but rather **inhibition of IMPDH in rapidly dividing intestinal epithelial cells**, which reduces their guanosine nucleotide pools and impairs cell division and barrier function. ### Why Option 1 Is Incomplete Option 1 correctly identifies IMPDH inhibition and isoform selectivity but **fails to explain the observed toxicity**. The question presents with both diarrhea (GI toxicity) and leukopenia (bone marrow toxicity). Option 1 implies that "relative sparing of other cell types" protects non-immune tissues — but this is only partially true. Rapidly dividing non-immune cells ARE affected because they also express IMPDH. ### Dose-Dependent Toxicity Profile | Toxicity | Mechanism | Onset | Frequency at 1–2 g/day | |----------|-----------|-------|------------------------| | **Diarrhea** | IMPDH inhibition in intestinal epithelium → ↓ cell turnover, barrier dysfunction | Days–weeks | 10–20% | | **Leukopenia** | IMPDH inhibition in bone marrow progenitors → ↓ WBC production | Weeks | 5–15% | | **Anemia** | IMPDH inhibition in erythroid progenitors | Weeks | 2–5% | | **Thrombocytopenia** | IMPDH inhibition in megakaryocytes | Weeks | <1% | **Clinical Pearl:** The patient's presentation (diarrhea + leukopenia at 2 weeks) is classic for MMF toxicity affecting both GI and hematopoietic tissues. Management includes: 1. Dose reduction (e.g., 500 mg BID instead of 1 g BID) 2. Antidiarrheal agents (loperamide, not diphenoxylate due to risk of toxic megacolon) 3. Monitor CBC weekly until stable 4. Consider switching to enteric-coated MMF (delayed-release formulation) if GI symptoms persist ### Mnemonic: IMPDH Inhibition Affects Dividing Cells **I**MPDH blocks **I**mmune and **I**ntestinal cells (both rapidly dividing) ### Why Option 3 Is the Best Answer Option 3 correctly identifies that MMF toxicity results from IMPDH inhibition in **both** intestinal epithelium (GI toxicity) and bone marrow (hematologic toxicity). This explains the patient's dual presentation. ### Why Option 4 Is Wrong Allergic hypersensitivity would present with rash, angioedema, or anaphylaxis — not selective GI and hematologic toxicity. The dose-dependent nature of the adverse effects argues against allergy. [cite:KD Tripathi 8e Ch 66; Harrison 21e Ch 283]
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.